DK1228768T3 - Medikament til beskyttelse imod trombotiske sygdomme - Google Patents

Medikament til beskyttelse imod trombotiske sygdomme

Info

Publication number
DK1228768T3
DK1228768T3 DK01130953T DK01130953T DK1228768T3 DK 1228768 T3 DK1228768 T3 DK 1228768T3 DK 01130953 T DK01130953 T DK 01130953T DK 01130953 T DK01130953 T DK 01130953T DK 1228768 T3 DK1228768 T3 DK 1228768T3
Authority
DK
Denmark
Prior art keywords
protection against
thrombotic diseases
drug
jaq1
active principle
Prior art date
Application number
DK01130953T
Other languages
Danish (da)
English (en)
Inventor
Bernhard Nieswandt
Original Assignee
Bernhard Nieswandt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bernhard Nieswandt filed Critical Bernhard Nieswandt
Application granted granted Critical
Publication of DK1228768T3 publication Critical patent/DK1228768T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK01130953T 2001-01-23 2001-12-28 Medikament til beskyttelse imod trombotiske sygdomme DK1228768T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101406A EP1224942A1 (fr) 2001-01-23 2001-01-23 Utilisation de JAQ1 (anticorps monoclonal anti-GPVI) en tant que médicament actif pour la protection contre les maladies thrombotiques

Publications (1)

Publication Number Publication Date
DK1228768T3 true DK1228768T3 (da) 2009-09-07

Family

ID=8176273

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01130953T DK1228768T3 (da) 2001-01-23 2001-12-28 Medikament til beskyttelse imod trombotiske sygdomme

Country Status (10)

Country Link
US (3) US20020141992A1 (fr)
EP (2) EP1224942A1 (fr)
JP (1) JP2002363100A (fr)
KR (1) KR20020062698A (fr)
AT (1) ATE432713T1 (fr)
AU (1) AU784917B2 (fr)
CA (1) CA2368791A1 (fr)
DE (1) DE60138867D1 (fr)
DK (1) DK1228768T3 (fr)
ES (1) ES2327604T3 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (fr) 2002-06-07 2003-12-10 Procorde GmbH Inhibiteurs de glycoprotéine VI et leur utilisation thérapeutique
WO2005008241A1 (fr) * 2003-07-07 2005-01-27 University Of North Carolina At Chapel Hill Procede et systeme de detection de multimeres du facteur von willebrand (vwf)
DE102004017295A1 (de) * 2004-04-05 2005-11-03 Zlb Behring Gmbh Verbindungen, welche die Entfernung von Rezeptoren von Zelllmembranen bewirken oder verhindern, und Verfahren zu ihrem Nachweis
WO2005111083A2 (fr) * 2004-04-29 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Anticorps diriges contre la glycoproteine vi et procedes associes
US7645592B2 (en) * 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
US20090041783A1 (en) * 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
CA2606450A1 (fr) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal anti-glycoproteine vi de membrane plaquettaire
JPWO2007091719A1 (ja) * 2006-02-07 2009-07-02 持田製薬株式会社 抗ｇｐｖｉ抗体の併用療法及び新規医薬用途
CA2646807A1 (fr) * 2006-03-31 2007-10-18 Mochida Pharmaceutical Co., Ltd. Nouveau marqueur de l'activation plaquettaire et son procede de determination
EP1916259A1 (fr) 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fragment SCFV anti-gycoprotéine VI pour le traitement de la thrombose
JP2008249552A (ja) * 2007-03-30 2008-10-16 Otsuka Pharmaceut Co Ltd 可溶性血小板膜糖タンパク質ｖｉの測定系
GB0713363D0 (en) * 2007-07-10 2007-08-22 Europ Cardiovascular Genetics Diagnosis and treatment of abnormal blood conditions
AU2008319336A1 (en) * 2007-10-31 2009-05-07 Otsuka Pharmaceutical Co., Ltd. Uses of a glycoprotein VI (GPVI) inhibitor
KR20100134677A (ko) * 2008-04-22 2010-12-23 체에스엘 베링 게엠베하 Ｇｐｖｉ의 억제에 의한 암의 예방 및 치료 방법
EP2336188A1 (fr) * 2009-12-18 2011-06-22 Sanofi-Aventis Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP2397495A1 (fr) * 2010-06-21 2011-12-21 Sanofi Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP2933269A1 (fr) 2009-12-18 2015-10-21 Sanofi Nouveaux anticorps antagonistes et leurs fragments fab contre le gpvi et utilisation de ceux-ci
CN108289939B (zh) 2015-08-05 2022-08-12 艾科迪科尔生物技术公司 抗人gpvi抗体及其用途
SG11201906530TA (en) 2017-02-03 2019-08-27 Acticor Biotech Inhibition of platelet aggregation using anti-human gpvi antibodies
BR112020013656A2 (pt) 2018-01-05 2020-12-01 Platelet Biogenesis, Inc. composições e métodos para produção de megacariócitos
JP7080352B2 (ja) 2018-05-16 2022-06-03 モルフォシス・アーゲー 糖タンパク質ｖｉを標的とする抗体
EP3813853A4 (fr) * 2018-06-29 2022-04-06 Platelet Biogenesis, Inc. Compositions pour l'administration de médicaments et leurs méthodes d'utilisation
EP4186512A4 (fr) 2020-09-14 2024-08-14 Advanced Protein Tech Corp Composition alimentaire pour soulager ou traiter une maladie cardio-cérébrovasculaire, et composition pharmaceutique pour prévenir ou traiter une maladie cardio-cérébrovasculaire, comprenant du 2'-fucosyllactose
KR102241938B1 (ko) * 2020-09-14 2021-04-20 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 뇌심혈관 질환 개선용 식품 조성물
EP4431526A1 (fr) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anticorps anti-gpvi et fragments fonctionnels de ceux-ci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9722320D0 (en) * 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US7928066B1 (en) * 1999-05-07 2011-04-19 Aventis Pharma Deutschland Gmbh Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use
US6406888B1 (en) * 1999-06-14 2002-06-18 Zymogenetics, Inc. Helical cytokine zalpha33
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof

Also Published As

Publication number Publication date
AU1198002A (en) 2002-07-25
EP1228768B8 (fr) 2009-09-09
US20040170624A1 (en) 2004-09-02
EP1224942A1 (fr) 2002-07-24
JP2002363100A (ja) 2002-12-18
US20070036784A1 (en) 2007-02-15
DE60138867D1 (de) 2009-07-16
ATE432713T1 (de) 2009-06-15
EP1228768A1 (fr) 2002-08-07
CA2368791A1 (fr) 2002-07-23
ES2327604T3 (es) 2009-11-02
AU784917B2 (en) 2006-07-27
US20020141992A1 (en) 2002-10-03
KR20020062698A (ko) 2002-07-29
EP1228768B1 (fr) 2009-06-03

Similar Documents

Publication Publication Date Title
DK1228768T3 (da) Medikament til beskyttelse imod trombotiske sygdomme
CU20200090A7 (es) Anticuerpos frente a entpd2 y terapias de combinación
BRPI0412245A (pt) anticorpos de rg1 e usos destes
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
WO2003078468A3 (fr) Utilisation d'une substance active se liant a cd28 pour la preparation d'une composition pharmaceutique
ATE208820T1 (de) Humanisierte antikoerper
NO20053435L (no) Immunoglobulinvarianter og anvendelser derav
PE20100251A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
NO20085104L (no) Antagonistisk anti-humant CD40-monoklonalt antistoff
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
GT200400181A (es) Anticuerpos dirigidos a m-csf
CR8485A (es) ANTICUERPOS CONTRA MAdCAM
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
NO20053101L (no) Kimaere og humaniserte antistoffer motalfa-5beta-1 integrin som modulerer angiogenese.
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
NO964013D0 (no) Monoklonale antistoffer som gjenkjenner TIE-reseptor og deres anvendelse
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
MA29595B1 (fr) Anticorps anti-cd40 humanises et procedes d'utilisation
NO960684L (no) Monoklonalt antistoff som induserer apoptose
EP1267925B8 (fr) Traitement des infections fongiques avec des antifongiques a base d'inhibiteur de synthase polyene ou beta glucane combines a des anticorps anti-hsp90
PE20230389A1 (es) Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
ES2109242T3 (es) Anticuerpos monoclonales contra inmunoglobulina e humana.
AU2002310996A1 (en) Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy
MX2023010567A (es) Variantes de anticuerpos no activadoras.